



Andreas Wildi

Dr. med. et lic. iur. HSG, Avvocato
Partner
Telefono +41 58 658 29 15
andreas.wildi@walderwyss.com

Andreas Wildi, born 1972, is a medical doctor and an attorney at law.

He advises and represents companies, associations and NGOs in the life sciences and healthcare sector.

His main focus is on reimbursement and pricing as well as regulatory affairs relating to pharmaceuticals and medical devices.

Andreas Wildi studied medicine at the University of Zurich and received his doctorate (Dr. med. / MD). While working part-time as a doctor in a hospital, in international rescue services and assisting / substituting general practitioners, he completed his law studies at the University of St. Gallen HSG (lic. iur. HSG). Before being admitted to the bar, Andreas Wildi was a clerk at a Cantonal Court and a trainee in a recognized Zurich business law firm. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health BAG. Andreas Wildi deepened his market access expertise internationally as EMEA market access law director for a large multinational life sciences company. Andreas Wildi has been a partner at Walder Wyss in Zurich and Berne since 2015.

Andreas Wildi works in German, English and French. He is admitted to the bar before all courts in Switzerland and is a guest lecturer in pharmaceutical law at the Law Faculty of the University of Lucerne and at the University of Bern's KPM Center for Public Management.



Publicazioni (selezione)

Swiss pharmaceutical reimbursement and pricing: Ordinance Law Changes (KVV/KLV) as of January 2024: Today's Decision by the Swiss Federal Council (Bundesrat)

di Andreas Wildi e Celine Weber
settembre 2023

Handbuch zum Lebensmittel- und Gebrauchsgegenständerecht

[Handbook on Foodstuffs and Utility Articles law]

Schulthess Verlag
di Annemarie Lagger, Andreas Wildi, Sophie Regenfuss, Celine Weber, Christine Leuch, Florian Roth, Hugh Reeves, Monja Sieber e Pandora Kunz-Notter

Editore: Daniel Donauer, Hugh Reeves und Celine Weber
Zürich, 2020

Triennial review of medicines' SL prices: Lessons learned from appeals won against the FOPH

di Celine Weber e Andreas Wildi
luglio 2023

The Revised Law on Human Genetic Testing

di Andreas Wildi, Lucina Herzog e Simon Mazidi

in: Life Science Recht, pag. 31-38, aprile 2023

Zugang zu nicht zugelassenen/nicht gelisteten Arzneimitteln: Ein wahrer Irrgarten

di Carole-Anne Baud, Reto Baumann, Jean-Christophe Devaud, Valérie Junod e Andreas Wildi

in: Aktuelle Juristische Praxis (AJP), pag. 176-182, febbraio 2023

Pharmaceutical Advertising 2022 - Switzerland

di Andreas Wildi e Celine Weber
in: Chambers Global Practice Guide, 2022

Kommentar zu Art. 5, 6 und 7a HMG

[Commentary on Art. 5, 6 und 7a HMG]
di Michael Isler [Co-autore], Andreas Wildi [Co-autore] e Stephanie Eggimann [Co-autore]

in: Eichenberger/Jaisli/Richli (Editore), "Basler Kommentar zum Heilmittelgesetz"
2, Basel, 2021

L'elenco completo delle pubblicazioni è disponibile su:

www.walderwyss.com/andreas.wildi